Immune Pharmaceuticals Inc. (IMNP) Stock Price & Overview
NASDAQ:IMNP
Current stock price
The current stock price of IMNP is 0.064 null. Today IMNP is down by -61.21%. In the past month the price decreased by -66.32%. In the past year, price decreased by -95.87%.
IMNP Key Statistics
- Market Cap
- 2.777M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.90
- Dividend Yield
- N/A
IMNP Stock Performance
IMNP Stock Chart
IMNP Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to IMNP. When comparing the yearly performance of all stocks, IMNP is a bad performer in the overall market: 99.83% of all stocks are doing better.
IMNP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IMNP. Both the profitability and financial health of IMNP have multiple concerns.
IMNP Earnings
IMNP Forecast & Estimates
IMNP Financial Highlights
Over the last trailing twelve months IMNP reported a non-GAAP Earnings per Share(EPS) of -1.9000000000000001. The EPS increased by 81.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.21% | ||
| ROE | -392.98% | ||
| Debt/Equity | 0.19 |
IMNP Ownership
About IMNP
Company Profile
Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. By blocking eotaxin-1, bertilimumab may prevent the migration and activation of eosinophils and other cells, thus blocking an important inflammatory pathway active in a variety of allergic and immune diseases. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporin, which is in late stage preclinical development for atopic dermatitis and psoriasis.
Company Info
Immune Pharmaceuticals Inc.
550 Sylvan Avenue
Englewood Cliffs NJ 07632
CEO: Elliot M. Maza
Phone: 201-464-2677
Immune Pharmaceuticals Inc. / IMNP FAQ
What does IMNP do?
Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. By blocking eotaxin-1, bertilimumab may prevent the migration and activation of eosinophils and other cells, thus blocking an important inflammatory pathway active in a variety of allergic and immune diseases. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporin, which is in late stage preclinical development for atopic dermatitis and psoriasis.
What is the stock price of Immune Pharmaceuticals Inc. today?
The current stock price of IMNP is 0.064 null. The price decreased by -61.21% in the last trading session.
Does IMNP stock pay dividends?
IMNP does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMNP stock?
IMNP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is Immune Pharmaceuticals Inc. (IMNP) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IMNP.
What is Immune Pharmaceuticals Inc. worth?
Immune Pharmaceuticals Inc. (IMNP) has a market capitalization of 2.78M null. This makes IMNP a Nano Cap stock.